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ABSTRACT

Cis-regulatory Sequence and Co-regulatory Transcription Factor Functions
in ERα-Mediated Transcriptional Repression

Richard LeRoy Smith
Department of Microbiology and Molecular Biology
Master of Science

Estrogens exert numerous actions throughout the human body, targeting healthy
tissue while also enhancing the proliferative capacity of breast cancers. Estrogen
signaling is mediated by the estrogen receptor (ER), which binds DNA and ultimately
affects the expression of adjacent genes. Current understanding of ER-mediated
transcriptional regulation is mostly limited to genes whose transcript levels increase
following estrogen exposure, though recent studies demonstrate that direct downregulation of estrogen-responsive genes is also a significant feature of ER action. We
hypothesized that differences in cis-regulatory DNA was a factor in determining target
gene expression and performed computational and experimental studies to test this
hypothesis. From our in silico analyses, we show that the binding motifs for certain
transcription factors are enriched in cis-regulatory sequences adjacent to repressed target
genes compared to induced target genes, including the motif for RUNX1. In silico

analyses were tested experimentally using dual luciferase reporter assays, which indicate
that several ER binding sites are estrogen responsive. Mutagenesis of transcription factor
motifs (for ER and RUNX1) reduced the response of reporter gene. Further experiments
demonstrated that co-recruitment of ER and RUNX1 is necessary for repression of gene
expression at some target genes. These findings highlight a novel interaction between ER
and RUNX1 and their role in transcriptional repression in breast cancer.
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Chapter 1: Estrogen Receptors and Transcriptional Repression

Estrogen Biology

Estrogens comprise a class of eight small, polycyclic steroid hormones, the most common
of which is 17-β Estradiol (E2). As steroid hormones, estrogens are cholesterol
derivatives that must be first synthesized at sites far from their target tissues. The primary
site of synthesis is within theca and granulosa cells of the ovaries in females, and leydig
cells in males. The final, rate-limiting step of estrogen synthesis involves aromatization
of an androgen precursor via cytochrome P4501. Following synthesis, estrogens are
transported through the blood in a dissociated state or are bound to sex-hormone binding
globulin and other transport molecules. Due to their hydrophobic nature, estrogens
readily diffuse across cell membranes once they arrive at target tissues.

After arriving at target tissues, estrogens and their cellular receptors (estrogen receptors
or ERs), regulate many aspects of healthy physiology including reproduction, bone
deposition and metabolism, and neural development2. In females, puberty is initiated by
gradual increases in serum concentration of estrogens in response to gonadotropin
signaling. Serum estrogen levels fluctuate most significantly during menstruation,
reaching the highest concentrations prior to ovulation2. Endogenous estrogens have also
been shown to be involved in aspects of male physiology, including spermatogenesis, and
cardiovascular development, and may be protective against coronary heart disease3.
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Tissues such as kidney, intestines, and lung exhibit moderate regulation by estrogens, but
they primarily target breast, uterus, brain, bone, endothelial cells, and the prostate gland.
Because estrogens affect a wide variety of tissue types, these studies necessitate work in
animal and cell culture models. Knockout studies in mice against ER or the P450
aromatase indicate that loss of estrogen signaling results in reduced bone deposition,
reduced male libido, and significantly reduced fertility in both males and females4. Very
few cases of human mutant variants of ER exist, presumably because the majority of
embryos possessing these mutations do not survive the first stages of development. In the
few recorded surviving cases, individuals present with decreased fertility and early onset
osteoporosis5.

Estrogen signaling is essential for sexual development and other aspects of healthy
physiology; however, estrogens and ERs are also involved in human diseases. In many
cases, a lack of estrogen signaling or reduced responsiveness to estrogen signaling play a
role in disease processes. Risk for cardiovascular disease in both men and women
improves in patients with increased estrogen signaling. In bone, a lack of estrogen
responsiveness leads to higher risk for osteoporosis. Disease phenotypes exhibiting
reduced estrogen responsiveness are also associated with stroke, Parkinson’s, and
Alzheimer’s disease all exhibit reduced estrogen responsiveness. In mouse models,
supplemental estrogens have been shown to decrease the risk of both stroke and
Alzheimer’s, by increasing the production of essential neurotransmitters6.
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While decreased estrogen responsiveness is associated with many disease phenotypes,
increased estrogen signaling also promotes disease phenotypes. Estrogens enhance
cellular proliferation, thus overexposure leads to an increased risk of DNA mutation.
Clinical and model organism studies indicate that this process of unchecked estrogenresponsive cell division increases the risk of developing cancer of the endometrium,
ovaries, large intestine, prostate, and breast6.

Several cancers are responsive to estrogen signaling; nevertheless, breast cancer is by far
the most common and best studied. In the US alone, breast cancer is diagnosed in one out
of every seven new cases of cancer. It is the third most common cancer overall and the
second most common cancer in women after skin cancer, and some 1500 men are also
diagnosed annually. According to the American Cancer Society7, in 2009 there will be an
estimated 194,280 new cases of mammary carcinoma and 40,610 associated deaths. The
healthcare and economic burden of breast cancer is also large, particularly in developed
nations where breast cancer is more common8. Nevertheless, as developing nations adopt
more affluent, Western lifestyles, breast cancers are increasing in frequency and cost of
treatment9-10. Understanding the link between estrogen signaling and breast cancer is of
major importance in both public and global health concerns11-12.

Breast Cancer and the Estrogen Receptor

The first direct indication of estrogen’s role in breast cancer was recorded in 1896 when
Dr. George Beatson of the Glasgow Cancer Hospital observed that bilateral oophrectomy
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in patients with inoperable neoplasia reduced the aggressiveness of these tumors13. This
pioneering procedure presented not only a viable treatment for aggressive breast cancers,
but also paved the way for the discovery that the ovaries regulate sexual development and
ultimately breast cancer14. Since then, it has been established that estrogens enhance cell
proliferation in breast tissue, a major feature of female reproductive development.
Additionally, estrogens have been found to foster development of neoplastic lesions, and
encourage progression from benign colonies into solid tumors and metastases15-17.
Because estrogens promote tumor development and progression, elevated blood estrogen
levels and increased duration from menarche to menopause are both considered
significant risk factors in breast cancer18-19. For this reason, most breast cancer therapies
focus on disruption or modulation of the effects of estrogen signaling.

The estrogens are often targeted for disruption using selective estrogen receptor
modulators or SERMs. SERMs are members of a class of pharmacological molecules
which compete with estrogen for occupancy of ERs, thus affecting downstream signaling
of estrogens. Unlike estrogens, SERMs do not purely act as agonists for ERs, nor are they
pure antagonists; instead, they exhibit tissue-specific modulation of ER signaling,
activating genes is some tissues which they inhibit in others20. For example Tamoxifen, a
SERM, is a common breast cancer drug. Tamoxifen signaling also exerts an overall
protective effect against osteoporosis, similar to E2. However, Tamoxifen treatment is
associated with a 2.5-fold increase in cervical and uterine carcinoma, complicating its use
in clinical practice. In contrast, Raloxifene, while exhibiting many of the beneficial
effects of Tamoxifen treatment in breast cancer and osteoporosis, exhibits none of the
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negative side effects in endometrial cancers21. In cardiovascular tissue, some SERMs also
appear to mimic some of the beneficial effects of endogenous estrogens. One reason for
this tissue specificity is tissue-specific expression of ERs and other interacting proteins.
Furthermore, SERMs alter ER conformation, which in turn affects the recruitment of
various co-regulators20. ERα directs breast tumor progression and aggressiveness, and it
follows that the majority of breast cancer treatments focus on modulating or antagonizing
ERα signaling.

The majority of estrogen functionality at the cellular level is mediated by the ER22, which
serves as the primary diagnostic and prognostic marker for breast cancer screening and
staging. Two known ER subtypes exist – ERα and ERβ – and ERα plays the more
clinically significant role in breast cancer; additionally, basic clinical classification of
breast cancers is a measure of ERα presence or absence23. In general, tumor ERα status
reflects the dependence of the tumor on estrogen signals for growth and proliferation.
Tumors which have lost or never exhibited estrogen responsiveness are usually more
invasive, do not respond to ERα-targeted treatments, and more difficult to treat24. In
general, breast cancers that lack ERα are associated with unfavorable disease outcomes
and poor patient survival23.

Estrogen Receptor and Transcriptional Regulation

The estrogen receptor was first described as a protein that bound 3H-Estradiol, and was
localized primarily in the nucleus22,25. Due to its subcellular localization and the increase
of cellular RNA content following E2 treatment, it was proposed that this receptor
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molecule was responsible for affecting gene expression, thus mediating the cellular
effects of known estrogen physiology22. As study of the molecule intensified, researchers
established that the tissue specificity of estrogen signaling is a result of the tissue-specific
expression of ER. Additionally, a second protein of similar structure was discovered in
1996, now known as estrogen receptor beta – ERβ26. The original molecule has since
been renamed ERα.

ERα is a member of the nuclear receptor superfamily of transcription factors, comprised
of hundreds of proteins. Most proteins in this superfamily respond to hormone signals,
alter gene expression, and possess similar structural features27. Structural regions are
divided into regions (A-E), each containing specific protein domains. The primary
transactivating domain, AF-1 resides near the N-terminus of the protein, occupying the
A/B region. The DNA binding domain (also known as the DBD) is located in region C,
close to the center of the protein, and is flanked on the C-terminal end by an unstructured
region D, also known as the hinge region. The ligand-binding domain (LBD) resides in
region E, following on the C-terminal side of the hinge region. In ERα, the LBD is
responsible for the majority of dimer stabilization following E2 binding and consists of 12
alpha helices which form a ligand-binding pocket28. This pocket binds estrogens, SERMs,
and several estrogen-like polycyclic compounds20. A unique feature of this region is helix
12, the second transactivating domain also known as AF-2. The domain exhibits estrogen
sensitivity and is only active once the ligand is bound. Once activated by ligand binding,
the conformation of AF-2 shifts, enabling ERα to mediate regulation of gene expression.
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ERα regulation of gene expression is ligand-dependent. Upon binding E2, ERα forms
dimers and moves to the nucleus. Once inside the nucleus, dimerized ERα binds DNA
sequences encoded by a 13-nucleotide motif (GGTCAnnnTGACC) also known as an
estrogen response element or ERE29-30. Recruitment of ERα depends on several factors
including number and location of EREs31, and the nucleotide composition of the ERE32.
ERE composition which has been shown to directly affect both affinity and activity of
ER binding suggesting that ERE sequence differences may result in alternate structural
conformations33. These conformational differences enable chromatin-bound ER to
physically interact with regulatory proteins and affect transcription of target genes.

The chromatin which ERα binds is dynamic, and necessitates modification in order to
regulate gene expression. Modifications are mediated by co-regulator proteins which
physically interact with ERα. These co- regulators include histone acetylase complexes,
chromatin remodeling complexes, and basal transcriptional machinery. Work done by
Métivier and colleagues demonstrates the overall cyclical, sequential pattern whereby
ERα and co-activators are recruited to the pS2/TFF1 promoter, including the subsequent
steps of ER degradation and recycling34. It appears that ERα binds to the pS2 promoter
four times in sequence, each time recruiting more protein complexes and further
modifying target chromatin. During the first sequence of events, ERα binds the ERE
adjacent to pS2, and recruits the SWI/SNF complex to transcriptionally silent DNA. This
is followed by binding of TBP and TFIIA. After this first round of recruitment, p68
associates with the ER-TBP complex, recruiting p300 and other proteins possessing HAT
(histone acetyltransferase) activity, which assemble to and unwind nascent chromatin. A
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third round of recruitment follows, re-recruiting components of SWI/SNF, further
modifying target chromatin. The final cycle of assembly further modifies chromatin via
acetylation, and culminates in the recruitment of mediator, polymerase, and
initiation/elongation factors. Following these cyclical rounds of protein recruitment,
transcription of pS2/TFF1 begins. Additionally, co-repressor molecules possessing
histone deacetylase (HDAC) activity are also cyclically recruited, silencing chromatin in
between activation cycles. Much is known about co-activator assembly following ERα
recruitment and is generally accepted as the general model of ER action on the molecular
level; however, recent data indicates that repression is also a major component of ERαmediated regulation of expression. This model of transcriptional repression runs counter
to the generally accepted model of activation by ERα.
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Transcriptional Repression by Estrogen Receptor

The induction-only paradigm is insufficient to describe the differential genome-wide
effects of ERα signaling in breast cancer cells. Microarray studies35, chromatin
immunoprecipitation coupled to paired-end ditag (ChIP-PET) experiments36, and other
whole genome analyses such as SAGE and ChIP-on-chip 37indicate that repressive effects
of estrogen on target genes are widespread. The ChIP-PET and ChIP-Chip studies
experiments in particular demonstrate that estrogen receptor is capable of binding to
thousands of sites throughout the genome adjacent to putative repressed target genes. In
the context of these studies, ERα binding regions have been found to reside as far away
as 150kb from target genes, though the majority occur within several kilobases. Each
study differs in platform, genes studied, and application, so the number of repressed
targets and binding sites varies, as do the sites and genes targeted. Direct causality is
difficult to establish in the context of microarray experiments; however, it appears that
ERα recruits co-repressors at ERα-binding sites directly repressing many of these E2responsive target genes.

Causative and Effective Mechanisms
Nuclear receptor co-repressors or CoRs are any proteins that interact with and lower the
transcriptional effects of nuclear receptors (NRs) on their target genes. Though a
relatively new discovery, much work has been done to identify these factors and their
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target NRs38. CoRs share several structural features, including a NR interacting domain,
consisting of an LXXLL sequence or NR Box, a L/IXXI/VI sequence called the CoRNR
(“corner”) Box, or other similar sequences39. In the context of ERα transcriptional
regulation, co-repressors mediate some of the tissue-specific effects of ERα signaling40,
binding surfaces usually bound by co-activators41. Generally, CoRs mediate
transcriptional repression by opposing the HAT activity of co-activators with HDAC
(histone deacetylase) activity, recruiting chromatin silencing complexes (Mi-2/NuRD42),
or through competing with co-activators for ERα binding. Recent thesis research
performed by Merrell and colleagues demonstrates that three CoRs (NCoR, NRIP1, and
SMRT) associate with ERα at sites adjacent to target genes, deacetylate histones, expel
co-activators, and abolish recruitment of polymerase43, thus directly affecting repression
of transcriptional activity.

Evidence suggests that ERα is capable of repressing gene expression by opposing
mechanisms used to activate gene expression; notwithstanding, it remains to be seen what
differences, if any, distinguish induction from inhibition of target genes. At binding sites
adjacent to down-regulated genes ERα recruits co-repressors as opposed to co-activators,
and it is thought that these differences are due to conformational differences in ERα20,41.
Nevertheless, the mechanisms that cause these conformational differences are unclear. It
is likely that the differences responsible for affecting ERα conformation exist at the
regulatory sequence level.
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We posit that features of ERα binding regions and cis-regulatory DNA adjacent to
repressed target genes are likely involved in differential regulation, including the
following:
1. Relative distance of the ERE from the transcriptional start site (TSS)
2. Composition of putative EREs,
3. Presence of motifs for other transcription factors
4. Distance of from the ERE to these other TF motifs.
5. Composition of ERE adjacent to these other TF motifs.
We carried out analyses to investigate these hypotheses on a genome-wide scale, using
breast cancer specific data. These analyses produced several inferences regarding
mechanisms of repression by ERα. Once the sequence differences were established, we
validated our findings experimentally.

In order to assess experimentally the cis-regulatory sequence requirements associated
with repressed target genes, we cloned several selected ERα binding regions into
luciferase gene reporter constructs and performed reporter assays (Chapter 3). We then
verified the physical presence of a transcription factor whose motifs occur adjacent to the
ERE using ChIP and re-ChIP experiments, RUNX1 (Chapter 4). These studies indicated
that RUNX1 binds to a motif adjacent to the SLC35A1 ERE, and interacts with ERα.
After validating the recruitment of this transcription factor, we tested its ability to repress
target gene expression by knocking down its expression with siRNA (Chapter 4). We
present here a mechanism whereby cis-regulatory sequence and transcription factor corecruitment regulate ERα mediated repression of target gene expression in breast cancer.
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Chapter 2: In Silico Analysis of Regulatory Sequence

Introduction

Several new genome-wide analysis of transcription factor binding have allowed for high
throughput detection of ERα binding regions. ChIP-PET technology isolates transcription
factor-bound DNA from standard ChIP procedures, amplifies the enriched DNA, and
uses plasmids and cloning strategies to generate sequencing libraries. These sequencing
products are then compared to the host species’ genome sequence in order to determine
location of transcription factor binding sites and the relative abundance with which those
binding sites are occupied by the transcription factor of interest. ChIP-chip technology
differs slightly in that it utilizes probe hybridization on a microarray surface to determine
the location and abundance of the fragment of interest. ChIP-seq is another variation,
similar to ChIP-PET, in which the ChIP DNA fragments are subjected to high throughput
sequencing. Recent studies by Edwin Cheung (unpublished) utilized a variation on the
ChIP-PET technology, combined with a microarray study. In these experiments, ChIP
DNA regions were correlated with their nearest gene. Data from these studies formed the
basis of our in silico analyses.

Our approach to solving the cis regulatory mechanisms behind ERα-mediated downregulation of gene expression utilized large-scale data sets of gene expression and ERα
binding regions throughout the genome. Specifically, the data sets were composed of
22

thousands of ERα binding regions from across the genome. Each ERα binding region was
then paired with an E2 responsive gene, obtained from microarray studies. Additionally,
each binding region was analyzed for the presence or absence of an ERE. We then
proceeded to investigate these data further using computational and statistical tools.

Our in silico analyses followed the design in Figure 1. After obtaining the compiled
binding region and gene expression data, they were then divided into two categories
based on their relative response to estrogen treatment versus a vehicle control. Binding
region-target gene pairs whose expression was activated following E2 treatment
comprised one group, while those whose expression was reduced following E2 treatment
comprised the other. Binding region-gene pairs that showed no E2 response were ignored
for our study. Next, sequence analyses were performed on each ERα binding region to
assess distinguishing differences between the two estrogen response categories based on
five features of repression-associated ERα binding regions:
1. Proximity of ERE to TSS
2. Relative nucleotide composition of ERE
3. Presence of other transcription factor motifs
4. Proximity of ERE to other TF motifs
5. Composition of ERE adjacent to other TF motifs
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Methods

Global ERE Proximity to TSS
Following compilation of the 1788 binding region-target gene pairs, the proximity of
each of the ERα binding region to their putative gene targets was determined and the
distances were compared between 850 activated and 938 repressed genes. Distance was
calculated as the nucleotide distance in bases from the closest edge of the binding region
to the annotated transcriptional start site of the target gene. The mean and median for
each distribution was calculated, and the log absolute difference of distributions of these
distances was compared for these two groups using a t-test.

Relative Composition of ERE
Putative EREs from each ERα binding region sequence were aligned and complied into a
batch file from each estrogen responsive category and then passed to WebLogo44
(http://weblogo.berkeley.edu/). WebLogo analyzes each position of the putative ERE for
the relative occurrence of each nucleotide and depicts the output in a Sequence Logo
format45. A sequence logo graphically depicts each position of aligned sequences as a
stack of the four nucleotide letters. The height of each nucleotide letter within the stack
represents its significance of occurrence at that position. The graphical logos indicate a
greater abundance with larger nucleotide letters, and less frequent occurrence with
smaller letters. The height of each letter is also indicative of statistical significance.
Sequence logos from both estrogen responsive categories were then visually compared to
25

assess ERE differences between EREs adjacent to activated and repressed target genes..
All 90 putative EREs adjacent to repressed genes were compared to all 95 ERE’s from
activated target genes, resulting in two sequence logos.

Transcription Factor Motif Occurrence in Regulatory Sequence
The center of each ERα binding region was calculated and sequences of 500 bases
flanking either side of these centers (1000 bases total) were compiled into a batch file and
categorized based on estrogen responsiveness. Each sequence was then submitted for
TRANSFAC46 (professional version 12.1) database analysis. The TRANSFAC database
is a collection of position-weight matrices representing transcription factor binding sites
based on biological and biochemical data. Parameters were optimized for non-redundant
vertebrate transcription factors, usage of high-quality matrices, and reduction of false
positives. We used the software package MATCH47 to analyze each sequence for the
presence of known TRANSFAC transcription factor motifs. The parameters used were
non-redundant, high quality, vertebrate position weight matrices, and set to minimize
false positives. Each motif from this analysis was analyzed for the frequency of
occurrence per region, and the frequency of occurrence within the repression versus the
induction category.

Following MATCH analysis, the motifs within each estrogen receptor binding nucleotide
sequence were counted and then motifs from repressed genes were compared to those
from activated genes. A Fisher exact test was performed utilizing the following factors:
presence of specific motif and E2-responsiveness. The resulting table of p-values
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indicates the significance of the frequency at which specific motifs occur adjacent to
repressed as opposed to activated target genes. In addition to this analysis, each factor
was further assessed for its frequency of occurrence in ERα binding regions which
contained putative EREs as opposed to those that did not.

Relative Proximity of ERE to Other TF Motifs
Following calculation of TF motif frequency of occurrence, the most highly enriched
motif adjacent to E2 repressed genes containing EREs – AML1 or RUNX1 – was
selected for further analysis. The nucleotide distances between the two closest edges of
each RUNX1 motif and ERE were calculated and averaged across all regions adjacent to
activated and repressed target genes. The distances between ERE-RUNX1motif pairs for
activated and repressed genes was then compared and calculated by T-Test of the log
absolute difference of distributions.

Relative Composition of EREs Adjacent to RUNX1 Motifs
EREs adjacent to RUNX1 motifs were arranged into 4 categories (Repressed, with
RUNX1 motifs; activated, with RUNX1; repressed, without RUNX1; activated, without
RUNX1) and analyzed using WebLogo according to the procedures described above.
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Results

ERE Proximity to Target Genes
After calculating distances from ERα binding regions to target gene TSS, distributions
were compiled and compared between repressed (Figure 2a) and activated (Figure 2b)
target genes. The independent variable in the analysis was established as the relative
distance of the ERα binding region to the TSS, and the dependent variable was the
number of binding sites (the graph displays this as density, which assumes the area under
the distribution curve equals 1and adjusts each value to yield a smoothed histograph).
The median distance was -6,403 adjacent to repressed target genes and -176 adjacent to
activated target genes. Negative numbers indicate relative upstream (5’) locations and
positive numbers indicate relative downstream (3’) locations. Statistical comparison (Ttest) of the log absolute differences in distributions of repressed vs. activated genes
yielded a significant difference (p=.001031), indicating that distance from ERα binding
regions to target gene TSS is a distinguishing characteristic of estrogen responsiveness in
the studied genes.
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ERE Composition Near Repressed Target Genes
In addition to our hypothesis that proximity of ERα binding regions to the TSS was a
significant feature in distinguishing activated and repressed genes, we postulated that the
composition of the ERE might be a distinguishing factor between activated and repressed
genes (Figure 3). An online sequence analysis tool, WebLogo, produced sequence logos
of EREs from both activated and repressed genes. The nucleotide composition
differences between activated and repressed target gene regulatory elements are slight,
and similar to the composition of the canonical ERE.

Frequency of Transcription Factor Motif Occurrence in Regulatory Regions
The nature of chromatin is such that no one state is fully “off” nor fully “on”. Instead, the
state of chromatin is dynamic, fluctuating according to the presence or absence of various
proteins and covalently linked molecules. Composition of the ERE appeared to be an
insignificant factor distinguishing repression from induction of target genes, suggesting
that ERα might not take on alternative conformations at activated genes versus repressed
genes.
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In addition to ERE composition, we questioned whether the presence of additional
proteins bound to regulatory motifs adjacent to the ERE would affect the interaction of
ERα with target genes. In other words, we postulated that transcription factors outside of
ERα might modulate the direction of ERα transcriptional regulation. This was
accomplished by searching for transcription factor specific motifs using TRANSFAC.
After comparisons, it was found (Table 1a) that 14 motifs occurred more frequently
within ERα binding regions containing EREs adjacent to repressed target genes (p<.05).
An additional 21 transcription factor motifs (Table 1b) occur with greater frequency
within ERα binding regions where the ERE is absent adjacent to repressed genes (p<.05).
Of those factors occurring in regions possessing EREs, motifs corresponding to AML1
(RUNX1) occurred most frequently overall with 196 occurrences adjacent to repressed
target genes and 112 occurrences adjacent to activated genes.
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Proximity of EREs to Nearby RUNX1/AML1 Motifs
Following the discovery that AML1 elements occur most frequently, we hypothesized
that if ERα interacted with RUNX1, the relative distances between ERE and RUNX1
motifs might be distinct in sites adjacent to repressed genes as opposed to activated
genes. This would indicate potential interactions between ERα and RUNX1. The
distribution of distances in sites adjacent to repressed genes was found to be distinct from
the distribution of distances from activated target genes (Figure 4). It appears that
adjacent to repressed target genes, a more normal distribution exists, with the average
distances being relatively close (mean=112, median=112). Adjacent to activated genes,
however, the distributions were bimodal and distributed further away (mean=156,
median=147). Statistical comparison of the distributions resulted in a p-value of
p=.005876.
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ERE Composition in ERα binding regions Containing RUNX1 Motifs
Evidence suggests ERE composition may affect ER conformation33, and since ERαRUNX1co-occurrence may be associated with repression of target gene transcription, we
hypothesized that the ERE composition in ERα binding regions containing RUNX1
motifs might be distinct. Data were divided into four categories based on estrogen
response and presence of the RUNX1 motif (Down, with; Up, with; Down, without; Up,
without – Figure 5). Utilizing analyses used to assess ERE composition globally, it was
found that the EREs within the ERα binding regions not containing RUNX1 did not
differ significantly from one another, taking on the appearance of analyses in Figure 3.

Conclusions and Discussion

In the first of our in silico analyses, comparison of the distributions of distances between
activated and repressed genes showed distinct differences. From these comparisons, we
identified the median distance of the ERE from active genes as being 176 bases upstream,
reasonably within the target gene promoter. However, median repression-associated
EREs fall significantly further upstream (approximately 6.4kb). Although it might be
likely that distance would prevent accessibility of E2-bound receptor from accessing a
target gene promoter, some gene enhancer regions may reside at sites more than 60kb
away48, thus, it may not follow that this would lead ultimately to repression of the target
gene. Instead, it is more likely that the effect of this distance is due to the spatial
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arrangement of chromatin49, suggesting that the distance of repressor sites from TSSs and
transcriptional factories may be an important feature of ERα function.

Compositional analysis of the ERE via Weblogo revealed very little differences between
EREs associated with repression and those associated with activation. This may be in part
due to the fact that the model for detection of the ERE is based on a consensus sequence
whose constituents were derived primarily from activated genes. This introduces a caveat
in utilizing such a model: if repression-associated EREs are actually distinct from
activation-associated EREs, differences are likely to be difficult to detect.

In addition to investigating the distance of ERE from target gene TSS, we hypothesized
that transcription factors other than ERα might bind sequence adjacent to the ERE, and
we investigated their presence TRANSFAC. The resulting list of transcription factors,
like any bioinformatics-based lists, was composed of statistically enriched TF motifs,
some of which had known interaction with cancer, and some of which had little known
biology at all.

In order to determine the functionality of selected regions and test the potential
involvement of statisitcally enriched TF motifs in ERα mediated transcripitonal
regulation, we decided to proceed with functional analysis via reporter assays.
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Chapter 3: Functional Analysis of Putative Regulatory Sequence

Introduction

Selection of Binding Sites Adjacent to E2-Repressed Target Genes
Hypotheses arising from computational and statistical analyses require further testing
experimentally to establish their validity. In the context of our in silico analyses, we
decided to first confirm that ERα binding regions actually function as repressive motifs
for associated target genes. Five binding sites adjacent to estrogen repressed target genes
ZNRF3, PSCA, NFIA, HES1, and SLC35A1 were chosen from the Merrell et al study as
candidates based on their relative proximity to the TSS 5’distal, 5’ proximal, intragenic,
3’ proximal and 3’ distal, respectively and represented a logical starting point for
validation of our in silico findings. ZNRF3, HES1, and NFIA were discarded during
preliminary studies due to performance inconsistencies. An additional site adjacent to the
E2 repressed gene MME was also added based on relevance to patient survival outcomes
in an independent, unpublished study (Chin-Yo Lin).

In previously conducted studies, Merrell and colleagues showed that each binding site
exhibited E2-responsive recruitment of ERα and co-repressors, de-recruitment of coactivators, deacetylation of histones, and expulsion of polymerase. Each site exhibited
similar repression-associated characteristics in terms of co-factor recruitment and reduced
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expression of target gene, nevertheless, each exhibited these characteristics in a slightly
different fashion. Moreover, TRANSFAC analysis of the binding sites adjacent to MME,
PSCA, and SLC35A1 (Figure 6) revealed the presence of several TF motifs found to be
significantly enriched adjacent to repressed genes. Even though the mechanisms for
involvement of these three genes in breast cancer remain unclear, they still represent a
sample of the potential mechanisms whereby ERα represses target gene expression in
breast cancer. Therefore, we proceeded to test the functionality of these DNA regions by
cloning the ERα binding regions for MME, PCSA, and SLC35A1 into reporter constructs
and performing reporter assays. Theoretically, if the region of DNA actually recruits ERα
in response to E2 treatment and in turn represses target gene expression, this would be
indicated by a reduction of luciferase activity in comparison to the control.
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Methods

Cell culture
MCF-7 cells are derived from a malignant adenocarcinoma of the breast, express
estrogen receptor, and are considered to be an effective model system for studying E2responsive breast cancer50.Adherent MCF-7 adenocarcinoma cells were obtained from
ATCC (ATCC Number HTB-22) and maintained at 37°C, 5% CO2, with 10% fetal
bovine serum suspended in phenol-red Dulbecco’s Modified Eagle Media (DMEM). Cell
passages were maintained below passage 20. Hormone starvation was maintained in 5%
charcoal-stripped fetal bovine serum suspended in phenol-red free DMEM. Though each
protocol’s serum starve was unique, all protocols require starve after cells reach at least
50-60% confluence. Following protocol-specific serum starve, cells were exposed to
10nM 17-β Estradiol (E2) for 45 min or 24 hours, depending on experiment. Passaging
was performed when cells were approximately 80% confluent.

Overview of Cloning, Luciferase Assay, and Analysis of ERα-Binding Site
DNA
In general, reporter assays test the function of a section of DNA in regulating the
expression of an easily measurable target gene. First, the target regions of DNA are
amplified via PCR and cloned into plasmids upstream of the reporter gene – in this case,
luciferase. The plasmids are transfected into the cell line of choice, MCF-7. Transfections
are followed by treatments such as estradiol and treatment-appropriate controls.
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Luciferase expression is assayed by adding luciferin and ATP, necessary substrates for
luciferase luminescence. Luminescence is then measured using a luminometer and
compared to control. In the context of the dual luciferase assay, secondary plasmids
containing a constitutively expressed Renilla luciferase gene are co-transfected with
individual firefly luciferase plasmids to provide a transfection efficiency background
control.

Cloning
To assess the role of ERα binding regions in regulating expression of associated target
genes, the regions adjacent to the remaining genes, MME, PSCA, and SLC35A1 were
cloned into luciferase gene reporter constructs amplified by conventional PCR using
DNA from MCF7 cells and primers from Table 2. PCR reagents were purchased from
Roche (FastStart High Fidelity PCR System, dNTPack, Cat. #04738284001). Cloning
enzymes were order from NEB (NheI and XhoI, Cat. #R0131S and #R0146S) and
Promega (T4 DNA Ligase Cat. #M1801). Following cloning, plasmids were amplified
using kits purchased from Qiagen (QIAprep Spin Miniprep Kit Cat. #27106, QIAGEN
Plasmid Midi Kit, Cat. #12145), and cloning was confirmed via cycle sequencing (ABI
3730xl DNA Analyzer).

Transfection
Following a 72-hr serum starve, cells in a 150mm cell culture dish at ≥80% confluence
were washed once with 1X PBS and removed by trypsin digest (2ml .05% Trypsin EDTA

43

with 2ml 1X PBS). Digested cells were suspended in 25ml (final volume) starve media.
500μl cell suspension was then aliquoted into 1ml starve media per well of a 24-well
plate and incubated for 24hrs at 37ºC. The following day, cells were ~80% confluent.
Individual transfection reactions were then prepared as follows: 6μl of firefly luciferase
plasmid (Promega, pGL3-Control, Cat. #E1714 and 2ERE-pGL4 gift from Edwin
Cheung) 250ng/μl and 6μl of Renilla luciferase plasmid (Promega, pGL4.75 hRlucCMV, Cat. #E6931 gift from Edwin Cheung) 250ng/μl were combined in 38μl of phenolred free DMED with no additives. Another tube was prepared with 5μl Fugene HD
transfection reagent (Roche, Cat. #04709705001) in 45μl additive-free DMEM. After
5min, both tubes were combined into a 15ml conical vial incubating at 25ºC for 1530min. After incubation, 3ml starve media were added to each 15ml conical vial and
mixed. The media was then removed from each well of the 24-well plate and 500μl of
transfection reaction was added to each well of one row of the 24-well plate. The 24-well
plate is then returned to incubation at 37ºC for 24hrs. After 24hr. incubation, starvation
media containing 10nM E2 or an equal volume of 100% EtOH is added to each well of
the 24-well plate and incubated at 37ºC for 24hrs. Following incubation, media is
removed and each well is washed once with 1ml 1X PBS before proceeding to Dual-Glo
Luciferase assay.

Dual-Glo Luciferase assay
The Promega Dual-Glo Luciferase Assay Protocol (Technical Manual TM058) was used
with modifications: 200μl of Dual-Glo Luciferase Reagent (Dual-Glo Luciferase Assay
System, Promega, Cat. #E2920) was added to each well of a 24-well plate, and allowed

44

to incubate at 25ºC for 10min and luciferase activity is measured with a FLUOstar
Optima Plate Reader using the Luminescence setting. This procedure was repeated with
200μl Dual-Glo Stop & Glo Reagent. Quantified firefly luminescence was then
normalized against quantified Renilla luminescence levels. The resulting ratios were then
averaged across replicates and the fold induction of luciferase luminescence was
calculated. Each set of transfection and luciferase assay experiments was fully replicated
three times, and averaged.

Site-Directed Mutagenesis
Site-specific mutants were generated to assess the functionality of relevant ERα binding
regions in modulation of reporter gene expression. Mutagenesis reagents were purchased
from Stratagene (QuikChange II Site-Directed Mutagenesis Kit, Cat. #200524), and
manufacturer’s protocols followed with modifications: 1μl each primer at 10μM
concentration, elongation for 15min per cycle, and use of LB broth during transformation
of E. coli instead of NZY+. Mutation specific primers were designed using Stratagene
Quick Change Primer Design Program
(http://www.stratagene.com/tradeshows/feature.aspx?fpId=118) and may be found in
Table 3. Following mutagenesis, colonies were picked, plasmids sequenced and
amplified following protocol from cloning.
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Results

MME, PSCA, SLC35A1
Of the five binding sites initially selected, only PCSA and SLC35A1 were retained for
further analysis. The PSCA (prostate stem cell antigen) gene codes for a membraneanchored glycoprotein and is overexpressed in many prostate cancers51. SLC35A1 (solute
carrier family 35 member A1) is a membrane-spanning transport protein responsible for
moving sialic acid across the Golgi membrane. A third gene and associated ERα binding
region was selected, MME (membrane metallo-endopeptidase), as an independent study
(Unpublished data, Chin-Yo Lin, 2007) demonstrated its association with positive
outcomes during adjuvant therapy for breast cancer. Like PSCA, MME is also highly
expressed in prostate neoplasia, and encodes a membrane bound peptidase52.

Establishment of reporter gene assays allowed for assessment of ERα binding regions’
ability to suppress target gene expression (Figure 7a). In comparison to positive and
negative controls, inserts corresponding to the binding sites adjacent to MME and PSCA
did not show significant E2-responsiveness as indicated by the ≤1 fold difference from
negative controls. The binding site for SLC35A1 did show E2-responsiveness, indicating
that ERα binding at this site does occur and does interact with transcriptional machinery.
An unexpected finding was that the response reflected an approximately 4-fold increase
in luciferase activity as opposed to a reduction as was expected. No other phenotypic
differences were noted.
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As mentioned previously, regions surrounding genomic EREs contain motifs for other
transcription binding. To extend the findings of the dual luciferase assays, we performed
site-directed mutagenesis to reduce the ability of target DNA to recruit putative
transcription factors involved in repression (Figure 7b).

We decided to investigate the binding sites for RUNX1 because they occurred more
frequently than any other TF motifs and had already been described as involved in cancer
mechanisms. RUNX1 motifs not only occurred more frequently adjacent to repressed
target genes, but also were associated with EREs whose composition was distinct
between activated and repressed genes. These findings suggest that while other
transcription factors may play a role in regulating ERα-mediated transcriptional
repression, RUNX1 was the most statistically sound factor to investigate.

Mutation of the ERE diminished luciferase activity, indicating that E2-responsive
induction of luciferase activity depends on both of these factors. The RUNX1 mutant
plasmid was not consistently lower than the unmutated control, but exhibited a trend of
reduced activity.

Conclusions and Discussion

The ERα binding region adjacent to SLC35A1 has been shown by Merrell and colleagues
to recruit ERα, co-repressors, allow for histone deacetylation, and expel polymerase – all
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within the context of a breast cancer cell line. Aside from this, SLC35A1 has little known
involvement in breast cancer. SLC35A1 is a sialic acid transporter commonly found in
the Golgi membrane, and is involved in sugar-nucleotide import for protein
modifications53-54. SLC35A1 expression in breast cancer has not been studied; however,
it has been shown to be a marker for osteosarcoma in mice and humans55. This finding is
intriguing and indicates a potential for SLC35A1/ERα involvement - ERα is responsible
for many processes in bone formation56-57 and breast cancer metastases often
preferentially colonize bone58-59.

Our findings indicate that while downstream events proceeding from ERα recruitment
may direct the effective mechanisms of transcriptional regulation, cis-regulatory DNA
sequence represents a dynamic environment which affects all downstream events.
Despite these findings, the reporter gene context proved insufficient to validate
repression. The binding site adjacent to SLC35A1 exhibited induction instead of
repression of the target gene. This anomaly may be due to the absence of histones and the
dynamic chromatin context present in vivo, indicating the importance of chromatin
remodeling in transcriptional repression. This hypothesis is strengthened by findings that
indicate that histone deacetylation is a putative hallmark of repression associated ERα
binding regions, specifically at the regulatory sequence adjacent to SLC35A1. To better
assess the role of cis-regulatory DNA elements in mediating transcriptional repression,
we chose to perform additional experiments that monitor the in vivo binding of DNA by
ERα.
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Chapter 4: RUNX1 Co-recruitment is Necessary for Estrogen
Receptor Mediated Transcriptional Repression of SLC35A1

Introduction

ER Interactions with Other Transcription Factors
Most studies of ERα signaling focus on ERα homodimers. Additionally, extensive
evidence indicates that ERα forms functional heterodimers with ERβ, as well as other
proteins23. Specifically, ERα has been shown to heterodimerize with transcription factors
such as Fos60, Jun61-62, and NF-kB63-64. The effects of these interactions are further
complicated by the fact that at some regulatory sites, ERα does not participate directly in
DNA binding at all, but is tethered to target chromatin via interactions with FOXA1 and
SP165-67. In short, the activity of ERα is dynamic, affected by various functional elements
and the chromatin context as a whole. Taken together, these observations indicate that
sequence adjacent to putative EREs may be responsible for recruiting various
transcription factors capable of affecting ERα regulation of target gene expression.

RUNX1 Biology and Carcinogenesis
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There were a large number of potential transcription factors, so preliminary work was
necessary to reduce the list of candidates. As previously described, TRANSFAC analysis
of regions adjacent to E2 target genes revealed that RUNX1 motifs occurred more
frequently than any other motif adjacent to repressed target sites, and thus was a prime
candidate for further screening. From a biological perspective, RUNX1 is an interesting
protein – it has known association with breast cancers and leukemias.

RUNX1 also known as AML-1, is a member of the core-binding factor alpha (CBFα)
class of transcription factors, and was first described in leukemia. CBFs usually consist
of heterodimers of a DNA-binding α subunit (RUNX1, RUNX2, or RUNX3) and a nonDNA-binding β subunit (CBFB). CBFs are necessary factors for hematopoesis68, and
their mutation is one of the most frequent events resulting in leukemogenesis69-70. Despite
its unclear role in breast cancer, RUNX1 expression is enriched in mouse mammary
tissue71, over expressed in many breast cancer cell lines72, and exhibits estrogenresponsiveness73-75, and has been shown to be a marker for breast cancer76-77. These
preliminary findings suggest that the motifs flanking the ERE, and the downstream
recruitment of transcription factors may be influential on overall regulatory effects, and
are therefore key to uncovering the underlying mechanisms of E2-mediate repression. The
most serendipitous finding was that a RUNX1 motif occurs within 80bp of the 3’ end of
the ERE on the ER binding site adjacent to SLC35A1. This discovery enabled functional
characterization of RUNX1 involvement at a site which was already being studied.
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During our functional characterization of MME, PSCA, and SLC35A1, it became clear
that with respect to the binding sites in question, the dual luciferase assays did not have
the capacity to adequately recapitulate the deacetylation of histones associated with target
gene repression. Thus, it was determined that an experimental system would have to be
established wherein an in vivo environment was more closely represented.
In order to select a more in vivo approach to monitoring the proteins associated with
chromatin, we selected chromatin immunoprecipitation (ChIP). ChIP does not assay the
level of gene expression, but rather the relative binding to DNA of a DNA binding
protein. In this case, the ChIP assay would focus on binding of RUNX1 to the SLC35A1
ER-binding site, and whether this binding occurs in combination with ERα. To confirm
the role of RUNX1 plays in ERα-mediated repression of SLC35A1, we used RNA
interference (RNAi) to disrupt RUNX1 expression. If RUNX1 actually participates in the
ERα-mediated repression of SLC35A1, RNAi knockdown of RUNX1 mRNA should lead
to a reversal of this repression.
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Methods

Cell culture
Cellular cultures were maintained as outlined in the Reporter Assay section. E2
treatments were performed for 45min (ChIP and re-ChIP) or 24hrs (siRNA).

ChIP
All chromatin immunoprecipitation assays followed previously described procedures34.
In summary, following a 72-hour serum starve, cells were treated with 10nM E2 or
vehicle for 45 min. After E2 treatment, cells were washed twice with 1X PBS, and
crosslinking performed with 1.5% Formaldehyde in PBS. Following crosslinking, cells
were washed, collected with cell scrapers and suspended in collection buffer. The cell
pellet was then washed once each with nuclear collection buffers - 1X PBS,
Nuclear/Chromatin Preparation Buffers I and II - in order to isolate cell nuclei. Following
nuclear isolation, nuclear suspensions were lysed in Lysis Buffer, sonicated on ice, and
centrifuged at 10,000-x g for 10min at 4ºC, and DNA-protein complexes collected from
supernatant. Aliquots were removed from these supernatant samples, and set aside as
inputs. The remaining supernatant samples were incubated in IP Buffer with antibodies
overnight with rocking at 4°C. After antibody incubation, IP samples were treated with
40μl of a 50% Protein A/Beads Buffer slurry and incubated further ≥3 hours. Following
incubation, beads were washed as follows: once each with Washing Buffers I-III, and
three times each with Washing Buffer IV. Following beads pellet washes, DNA-protein
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complexes were extracted from beads solution with Extraction Buffer. Input and IP
samples were then de-crosslinked overnight at 65°C to evaporate formaldehyde. DNA
was then purified using the Qiagen PCR Cleanup Kit, eluted in 25μl ddH2O, and stored at
-20°C. Relative abundances of DNA were quantified via qPCR in 96-well plates utilizing
a Roche Light Cycler 480. Each reaction consisted of 1μl DNA extraction, 5μl SYBR
Green, 5pmoll each forward and reverse primers, and 3μl ddH2O. Primer sets may be
seen in Table 4. Experiments were further visualized by running PCR products on a 1%
agarose gel.

Re-ChIP
Re-ChIP deviated from standard ChIP procedures during the first immunoprecipitation
(IP). After incubating ChIP samples with ERα antibody overnight, 40μl beads slurry was
added and incubated as usual. Beads were then washed once with Washing Buffer I and
twice with Washing Buffer II, extracted three times with 100mM DTT, and resuspended
in Re-ChIP Buffer. Secondary (RUNX1) antibodies were then added, and the remaining
procedures follow standard ChIP protocol. Experiments were further visualized by
running PCR products on a 1% agarose gel.

SiRNA knockdown of RUNX1
Cells at 80% confluency were seeded ~1 part in 25 to 6-well plates. After reaching 50%
confluency in 6-well plates, media was removed and transfection reagents added
following protocol from Dharmacon. In summary, 3μl Dharmafect A reagent in 197μl
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additive-free DMEM were combined with 2.5μl SMART pool siRNA (Dharmacon, Cat.
# LQ-003926-00) in 197.5 μl additive-free media, incubating at room temperature for
≥40min. Following incubation, 400μl transfection reaction was added to each well, and
treatment lasted for 24 hours. After 24-hour incubation, each well was treated with 10nM
final concentration E2 or ethanol vehicle and incubated for another 24 hours. Upon
completion of E2 treatment, cells were lysed and RNA extracted with 1ml Trizol (TRIzol
reagent Invitrogen, Cat. #15596-026) following manufacturer’s protocol. Trizol-extracted
RNA aliquots were quantified with Nanodrop mass spectrometry, and diluted (if
necessary) to 1μg/μl concentration and stored at -80°C.

Reverse transcription of RNA into cDNA was performed on RNA extraction samples
using Promega ImProm II (Promega, Cat. #A3800) reverse transcription reagents and
protocols using 20μl reactions. Equal quantities (1μg) of RNA were reverse transcribed in
order to maintain consistency between samples and control for variation in cell count and
confluency. Final cDNA products were suspended 1:5 in 100μl ddH2O and stored at 20°C. Relative RNA expression levels were quantified using SYBR Green qPCR
(Lightcycler 480 SYBRGreen I Master, Roche, Cat. #04707516001) reagents performed
in 96-well plates in a Roche Light Cycler 480 PCR machine. Each PCR consisted of 4μl
diluted cDNA, 5μl SYBR Green, 5pmol each forward and reverse primers. Primer sets
used are shown in Table 7. Experiments were further visualized by running PCR products
on a 1% agarose gel.
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Results

In order to determine the binding of RUNX1 to the ERα binding region, we performed
ChIP assays (Figure 8). ChIP primarily allows relative quantification of DNA bound by
transcription factors or other DNA binding proteins. RUNX1 binding was first assayed
and quantified with qPCR using SYBR Green reagents. At the SLC35A1 ERα binding
region, RUNX1 associates with target DNA, binding ~40 fold over the SLC35A1 exon 4
negative control (Figure 8a-b). It also appears that this association is E2-independent, as
indicated by the overlapping ranges in standard errors on the RUNX1 binding results
distribution and results from a PCR run on agarose gel (Figure 8c).

We followed the RUNX1 ChIP with a re-ChIP to test the hypothesis that at regulatory
DNA adjacent to repressed target genes, RUNX1 and ERα are in the same molecular
complex. The ERα ChIP product was immunoprecipitated with a secondary ChIP against
RUNX1 and found that RUNX1 and ERα do co-recruit to the SLC35A1 regulatory
sequence 50% (E2-) and 80% (E2+) greater than inputs while SLC35A1 exon 4 negative
control recruitment in negligible(Figure 9a). In addition to this finding, it appears that
though RUNX1 recruitment is E2-independent, E2 signaling is still necessary for corecruitment of ERα, indicated by a ~1.5-fold increase in binding of SLC35A1 ERE
following E2 treatment (Figure 9b). PCR products were also run on an agarose gel
(Figure 9c)
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In order to test the role of RUNX1 in regulating SLC35A1 expression, we performed
RNAi knockdown against RUNX1and quantified the results with qPCR (Figure 10).
Following knockdown, RUNX1 is knocked down approximately 5-fold following siRNA
treatment. This knockdown appears to be E2-independent (Figure 10a), suggesting that
RUNX1 binds the ERα binding region independent of ERα recruitment. The typical ~2
fold repression of SLC35A1 is reversed following RUNX1 knockdown (Figure 8B),
indicated by a ≤1 fold difference from control treatments and PCR products were run on
an agarose gel (Figure 10c).

Conclusions and Discussion

In the context of SLC35A1, RUNX1 binding is key to E2- mediated repression. RUNX1
binds the SLC35A1 ERα binding region prior to E2 treatment, and may thus be
responsible for establishing an appropriate context for ERα recruitment of co-repressors
and other events necessary for transcriptional inhibition. In the absence of RUNX1, ERα
is no longer sufficient to repress SLC35A1 expression, perhaps due to conformational
differences. The physical differences in repressive and activating conformations may be
slight, though they are not investigated in this study. Regardless of the extent to which
ERα conformational shifts take place following RUNX1 co-recruitment, this event is
sufficient to promote co-repressor recruitment and activity and inhibit co-activator
activity, perhaps by eliminating the interface for co-activator action. It is also unclear
whether ERα and RUNX1 physically interact, or whether they are
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simply present as a part of a larger repressor complex. Future extensions to investigate
RUNX1 and ERα interactions and to identify other components essential for repression
may include co-immunoprecipitation (Co-IP), competitive binding assays, and alterations
of ERα binding interfaces with SERMs. Additionally, siRNA titrations against ERα and
RUNX1 may indicate threshold levels necessary for transcriptional repression.
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Chapter 5: Summary and Conclusions

Mechanisms of ERα-Mediated Transcriptional Repression

Estrogen receptor action in response to E2 exposure is necessary for healthy physiology,
but is also a hallmark of malignant breast cancer. Breast cancer staging and
aggressiveness are commonly assessed based on ERα expression status. ERα binds E2
and thus mediates its effects on healthy physiology as well as breast cancer. By binding
to response elements throughout the genome, E2-bound ERα recruits various chromatin
remodeling and transcriptional machinery, thereby modulating the expression of many
genes. Though the majority of known E2-responsive genes from previous studies are
activated following exposure to E2, our most recent findings indicate that ERα binds to
more binding regions adjacent to repressed targets than those associated with activation.
Cis-regulatory sequence differences are likely the cause of the characteristics that
distinguish mechanisms whereby ERα possess the ability to both activate and repress
gene activity. In order to assess the role that these cis-regulatory sequences play in
affecting ERα regulation of gene expression, we performed computational analyses of
ERα binding and effects on gene expression on genome-wide scale.

Our in silico analyses indicate that binding sites associated with repressed target genes
are located significantly more distal to the TSS than those associated with activated
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target genes. This suggests that accessibility to the target gene promoter is an important
factor in determining level and direction of gene expression. We also found that ERE
composition does not significantly distinguish repression from activation, suggesting that
it is not a major determinant of ERα-mediated transcriptional control. Furthermore, many
motifs associated with the recruitment of other transcription factors are present at greater
frequency in ERα binding regions adjacent to repressed target genes as opposed to
activated target genes. The most frequently occurring of these transcription factor motifs
corresponds to AML1/RUNX1, a transcription factor involved in leukemias. Given the
frequency with which RUNX1 motifs occur adjacent to repressed target genes, it is
possible that RUNX1 is a common mediator of ERα repression of target genes. This
hypothesis is strengthened by the fact that although ERE composition is not significantly
different between activated and repressed genes, EREs associated with RUNX1 motifs do
exhibit differences at more than one position, which may suggest that when in the
presence of RUNX1, ERα adopts a repressive conformation resulting in recruitment of
co-reprepressors and repression of target genes.

Following our in silico analyses, we performed functional in vitro and in vivo assays to
validate and extend our findings. First, we utilized dual luciferase assays combined with
mutagenesis studies of binding sites adjacent to confirmed E2-repressed target genes.
These binding sites did not adequately recapitulate the in vivo chromatin context, still
they indicated that the ERE and the RUNX1 motif are both necessary for the estrogen
mediated response of the binding site adjacent to SLC35A1, a known marker for
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osteosarcoma. It appears that in the absence of either factor, target gene regulation is
diminished.

After finding that the reporter assay system did not mimic the in vivo context of ERα
binding, we performed ChIP assays to determine RUNX1 and ERα-RUNX1binding to
repression-associated ERα binding regions. Our ChIP studies indicate that RUNX1 binds
to the SLC35A1 ER binding site approximately 70 bases from the ERE. Though RUNX1
binding is E2-independent, re-ChIP indicated that E2-responsive ERα co-assembles with
RUNX1 at the SLC35A1 ERα binding region. More importantly, siRNA knockdown of
RUNX1 reverses the E2-responsive repression of SLC35A1, demonstrating that RUNX1
recruitment is necessary for SLC35A1 repression by ERα (Figure 11). This supports the
findings of the reporter gene assays, which indicate that removal of either ERα or
RUNX1 signaling abolishes their combined effect on target gene expression.

Given that SLC35A1 involvement in breast cancer is unknown, assessing the direct effect
of RUNX1-ERα co-recruitment in breast cancer is difficult. RUNX1 elements occur with
greater frequency than any other transcription factor motif in regulatory DNA adjacent to
repressed target genes, and it is likely that RUNX1 plays a role in modulating ERα
signaling at many sites in the genome. Additionally, the presence of both ERα and
RUNX1 is required in order to mediate transcriptional repression of SLC35A1,
suggesting that if similar binding sites exist, they may potentially be regulated by the
same mechanisms. E2 signaling is responsible for cellular proliferation, and in the context
of RUNX1-ERα co-recruitment, it may be responsible for the repression of tumor
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suppressor-like anti-growth genes. Thus, RUNX1 may be a potential target for future
pharmacological studies, whose knockdown may allow the expression of suppressed
growth-inhibitory genes in breast tumors.

Future Directions

Unpublished data from Merrell and colleagues suggest that siRNA knockdown of a single
co-repressor is insufficient to completely abolish transcription of SLC35A1, but instead
requires simultaneous knockdown of SMRT, NCoR, and NRIP1. In the case of RUNX1,
single knockdown is sufficient to abolish transcriptional repression, suggesting that
RUNX1 may play a key role in the assembly of a repressor complex at the SLC35A1
regulatory region. The existence of such a complex has already been proposed78, and due
to widespread occurrence of the RUNX1 motif adjacent to 39% of E2-repressed genes
also possessing EREs throughout the genome, a RUNX1-repressor complex may play a
similar role at other ERα binding regions. Future studies may pursue this further through
co-immunoprecipitation (Co-IP) of RUNX1 and ERα, as well as other components of the
hypothetical repressor complex.
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Given that the ERα-responsive assembly and recruitment of co-factors and transcriptional
machinery at the pS2 promoter is not static, but rather a dynamic, cyclical, array of
sequential assembly and disassembly, the role of RUNX1 may be less integral to the
formation of an overall complex. Instead, RUNX1 may represent a key step within a
similar ERα-responsive, dynamic assembly of co-repressors and other chromatin
remodeling machinery, leading to the winding up of active chromatin, and perhaps the
modification of histones through methylation or other covalent modifications (Figure 12).
Elucidation of these and similar mechanisms necessitate extensive ChIP and re-ChIP of
putative co-factors and other proteins. In addition to ChIP and re-ChIP experiments,
identification and screening of other components via yeast-2-hybrid assays may also be
pursued to screen multiple interacting partners in a high-throughput fashion.

Elucidation of the mechanisms behind RUNX1-ERα co-recruitment and interaction
represents a major break from previous understanding of ERα function in breast cancer.
Unlike preceding studies, we have demonstrated that target gene activation is not ERα’s
sole function, and perhaps not even its major function. In this context, ERα functions as
an effector of proliferative signals, repressing the expression of hundreds of genes
possibly involved in regulating cell growth. Many of these repression-associated ERα
target genes may even be tumor suppressors. Perhaps, if newer treatments are more
focused on co-recruited factors like RUNX1, or used in combination with current
adjuvant therapies, the mechanism behind ERα-RUNX1 transcriptional repression may
ultimately lead to more targeted and effective breast cancer therapies with fewer side
effects on the wide range of ERα target tissues.
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